Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of rituximab with CHOP every 14 days versus every 21 days in newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma
2004-002197-34Phase 3Completed
- Sponsor
- University College London
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University College London. Primary endpoint: Overall survival. Started Feb 2005; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2004-002197-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002197-34.